AstraZeneca Plc is focusing on the US market for growth due to challenges in China impacting the company's share price.

CEO Pascal Soriot outlined the company's strategic ambitions in the US, including significant investments in research and development.

Despite ongoing difficulties in China, AstraZeneca reported optimistic third-quarter earnings and raised its annual forecast. This shift highlights the company's commitment to expanding its presence in the US pharmaceutical landscape amidst a turbulent environment in China.